Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gadodiamide→

Gadodiamide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
131410-48-5
Molecular formula
C16H26GdN5O8
Molecular weight
573.66 g/mol
Drug class
Gadolinium-based MRI contrast agentlinear non-ionic gadolinium chelate
Mechanism of action
The intact gadolinium chelate is paramagnetic and shortens T1 relaxation times to increase MRI signal intensity in tissues where it distributes. It is a diagnostic contrast complex, and its use is restricted or contraindicated in patients at risk of nephrogenic systemic fibrosis (NSF).
Indications / reported uses
  • Historical contrast-enhancement use for MRI of the central nervous system and selected body regions; gadodiamide is contraindicated or heavily restricted in severe renal impairment in many jurisdictions due to NSF risk. Verify current local availability and product status.

Sources: EMA — Gadolinium-containing contrast agents referral · US DailyMed — OMNISCAN (gadodiamide) · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Gadolinium-based MRI contrast agent; linear non-ionic gadolinium chelate

Mechanism of action

The intact gadolinium chelate is paramagnetic and shortens T1 relaxation times to increase MRI signal intensity in tissues where it distributes. It is a diagnostic contrast complex, and its use is restricted or contraindicated in patients at risk of nephrogenic systemic fibrosis (NSF).

General use cases

  • Historical contrast-enhancement use for MRI of the central nervous system and selected body regions; gadodiamide is contraindicated or heavily restricted in severe renal impairment in many jurisdictions due to NSF risk. Verify current local availability and product status.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Gadodiamide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gadodiamide Permitted Daily Exposure (PDE) report (the Gadodiamide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gadodiamide Occupational Exposure Limit (OEL) report (the Gadodiamide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.